BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained…
<!-- Name:DistributionId Value:8755977 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
berotralstat
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of…
<!-- Name:DistributionId Value:8742059 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved…
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE…
RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 and…
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of…
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts, including one…
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and…
RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy…